The Patent Finder

Terms ending in 2033

CureVac AG

Every in-force patent on CureVac AG's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,690,910Pharmaceutical Composition Comprising a Polymeric Carrier Cargo Complex and at Least One Protein or Peptide Antigen
In force
 · Medium confidence
Curevac SEIn forceMedium confidence
US 9,683,233Artificial Nucleic Acid Molecules for Improved Protein or Peptide Expression
In force
 · Medium confidence
Curevac SEIn forceMedium confidence
US 10,047,375Artificial Nucleic Acid Molecules
In force
 · Medium confidence
Curevac SEIn forceMedium confidence
US 10,738,306Artificial Nucleic Acid Molecules for Improved Protein or Peptide Expression
In force
 · Medium confidence
Curevac SEIn forceMedium confidence
US 11,458,193Combination of Vaccination and Inhibition of MHC Class I Restricted Antigen Presentation
In force
 · Medium confidence
Curevac SEIn forceMedium confidence
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited